Autolus Therapeutics plc

The momentum for this stock is not very good. Autolus Therapeutics plc is not a good value stock. Autolus Therapeutics plc is not a good growth stock. Autolus Therapeutics plc is a mediocre stock to choose.

Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer tre...

News

Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024

Globe Newswire Tumor Burden (TB)-guided dosing strategy, together with the unique fast off-rate binder of obe-cel, resulted in substantial response and low incidence of Grade 3 immunotoxicityTB-guided dosing of...\n more…

Financial Analysis: Autolus Therapeutics (NASDAQ:AUTL) & Cognition Therapeutics (NASDAQ:CGTX)

Ticker Report Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) and Cognition Therapeutics (NASDAQ:CGTX - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare...\n more…

Is Autolus Therapeutics (NASDAQ:AUTL) Using Debt Sensibly?

Simply Wall St Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...\n more…

Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up to $3.64

Zolmax Shares of Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $3.64, but opened at $3.80. Autolus Therapeutics...\n more…

Autolus Therapeutics plc (AUTL) Q2 2024 Earnings Call Transcript

Seeking Alpha: Transcripts Autolus Therapeutics plc (AUTL) Q2 2024 Earnings Call Transcript...\n more…

Buy Rating Affirmed for Autolus Therapeutics Amid Strong Commercial Prospects and Solid Financials

TipRanks Financial Blog Deutsche Bank analyst James Shin reiterated a Buy rating on Autolus Therapeutics (AUTL - Research Report) today and set a price target of $10.00. J...\n more…